Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Iloperidone Tablets, 1 mg, 2. mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to market a generic equivalent of Fanapt® Tablets, 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg of Vanda Pharmaceuticals Inc. The product will be manufactured at Lupin's facility in Goa, India.
Iloperidone Tablets (RLD Fanapt®) had estimated annual sales of USO 162 million in the U.S. (IQVIA MAT March 2022).
Shares of Lupin Limited was last trading in BSE at Rs. 726.25 as compared to the previous close of Rs. 726.50. The total number of shares traded during the day was 22613 in over 1317 trades.
The stock hit an intraday high of Rs. 744.10 and intraday low of 724.75. The net turnover during the day was Rs. 16582849.00.